Skip to content

Trial Summary

This study aims to investigate effect of Nivolumab and Temozolomide vs Temozolomide alone on overall survival in newly diagnosed elderly patients with glioblastoma.



ACTRN/NCT /ethics:


Scientific title:

A randomised phase II study of nivolumab and temozolomide vs. temozolomide alone in newly diagnosed elderly patients with glioblastoma (NUTMEG)

Sponsor / Cooperative group:


Trial & Patient Characteristics

Cancer TypeBrain & central nervous system
Trial TypeTreatment
PhasePhase II
Age Range65 and older
Tumour StreamGlioblastoma
Cancer StageAll stages
Anticipated Start Date2018-01-15
Anticipated End Date2022-03-01

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Phone08 7074 2342
Principal InvestigatorDr Hien Le
Recruitment StatusRecruiting
HospitalFlinders Medical Centre
Clinical Trial CoordinatorHannah Adelson
Phone08 8206 4835
Principal InvestigatorDr Ganessan Kichenadasse
Recruitment StatusRecruiting